| Central Venous Catheter-related Complications in Patients Under Anticancer Treatment (NCT05455866) | Centre Hospitalier Alpes Leman | 2022-07-11 |
| A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors (NCT06245330) | Ascentawits Pharmaceuticals, Ltd | 2022-07-07 |
| A Study of TRK-950 in Patients With Advanced Solid Tumors (NCT05423262) | Toray Industries, Inc | 2022-07-06 |
| A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects (NCT05440006) | Jiangsu HengRui Medicine Co., Ltd. | 2022-07-03 |
| Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 (NCT05383482) | Laekna Limited | 2022-07-01 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors (NCT05244551) | Abbisko Therapeutics Co, Ltd | 2022-06-30 |
| CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors (NCT05436093) | Peking University Cancer Hospital & Institute | 2022-06-23 |
| Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) (NCT05403177) | University Health Network, Toronto | 2022-06-23 |
| Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors (NCT06258330) | Aummune Ltd. | 2022-06-22 |
| High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis (NCT05301101) | Medical College of Wisconsin | 2022-06-13 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500) | Bristol-Myers Squibb | 2022-06-09 |
| An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition (NCT05390944) | Impact Therapeutics, Inc. | 2022-06-08 |
| A Study of ASP3082 in Adults With Advanced Solid Tumors (NCT05382559) | Astellas Pharma Inc | 2022-06-08 |
| An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition (NCT05391048) | Impact Therapeutics, Inc. | 2022-06-06 |
| Universal Germline Testing in the Community (NCT05416710) | Invitae Corporation | 2022-06-01 |
| A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors (NCT05385692) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-06-01 |
| A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors (NCT05217693) | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | 2022-06-01 |
| Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients (NCT05369312) | Betta Pharmaceuticals Co., Ltd. | 2022-06-01 |
| The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment (NCT06039137) | Erasmus Medical Center | 2022-06-01 |
| Camrelizumab Combined With Apatinib Mesylate (NCT05380986) | Henan Cancer Hospital | 2022-05-20 |
| Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol (NCT05390827) | Memorial Sloan Kettering Cancer Center | 2022-05-19 |
| A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors (NCT05528055) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-05-18 |
| A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (NCT05346484) | Imugene Limited | 2022-05-17 |
| Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas (NCT05833984) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-05-17 |
| NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors (NCT05382377) | jianming xu | 2022-05-17 |
| Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition (NCT05336279) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-11 |
| Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors (NCT07121829) | Day One Biopharmaceuticals, Inc. | 2022-05-02 |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors (NCT05076760) | Memgen, Inc. | 2022-04-21 |
| Study of ASN004 in Patients With Advanced Solid Tumors (NCT04410224) | Kirilys Therapeutics Inc. | 2022-04-08 |
| A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors (NCT05176509) | Eucure (Beijing) Biopharma Co., Ltd | 2022-04-05 |
| A Dose Finding Study to Treat Bone Tumor(s) (NCT06008483) | QSAM Therapeutics, Inc. | 2022-04-05 |
| The Intersection of Oncology Care and Worker Well-Being (NCT05250284) | University of Colorado, Denver | 2022-04-04 |
| ERK Inhibitor JSI-1187 in Advanced Solid Tumors (NCT06239623) | JS InnoPharm, LLC | 2022-04-02 |
| RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid Tumors (NCT05284968) | Peking University | 2022-04-01 |
| A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors (NCT05165849) | Zhejiang Genfleet Therapeutics Co., Ltd. | 2022-04-01 |
| HCW9218 in Select Advanced Solid Tumors (NCT05322408) | Masonic Cancer Center, University of Minnesota | 2022-04-01 |
| Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer (NCT05525767) | Hebei Medical University Fourth Hospital | 2022-03-31 |
| A Phase I Study of IBI325 in Patients With Advanced Solid Tumor (NCT05246995) | Shandong Cancer Hospital and Institute | 2022-03-23 |
| Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors (NCT05262530) | BioNTech SE | 2022-03-22 |
| Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy (NCT05206942) | Stanford University | 2022-03-21 |
| A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 (NCT05323045) | Byondis B.V. | 2022-03-21 |
| A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors (NCT05198752) | Stemirna Therapeutics | 2022-03-18 |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (NCT05169437) | Tempus AI | 2022-03-15 |
| Hyperthermia With Flexible Electrode-typed 2-MHz Device During Radiotherapy for Solid Tumors (NCT05282784) | Yonsei Hyperthermia Study Group | 2022-03-10 |
| Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases (NCT06613295) | Cancer Research Antwerp | 2022-03-07 |
| An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors (NCT05274191) | Zhongshan Hospital Xiamen University | 2022-03-04 |
| Performance Evaluation of Diagnostic Accuracy of PanTum Detect Test for Detection of Solid Tumours in Known Cancer Population and in Cancer Free Population. (NCT06456216) | Max Healthcare Insititute Limited | 2022-02-21 |
| Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China (NCT05120375) | Bio-Thera Solutions | 2022-02-17 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (NCT05103358) | Aadi Bioscience, Inc. | 2022-02-15 |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors (NCT05269316) | Impact Therapeutics, Inc. | 2022-02-11 |
| A Phase I Study of IBI325 in Patients With Advanced Solid Tumor (NCT05119998) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-02-08 |
| Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors (NCT06535009) | Ono Pharmaceutical Co., Ltd. | 2022-02-08 |
| Study of NIB101 in Participants With Advanced Solid Tumors (NCT05192174) | Noile-Immune Biotech, Inc | 2022-01-24 |
| A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors (NCT05173142) | Hutchison Medipharma Limited | 2022-01-22 |
| Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors (NCT04987112) | CanWell Pharma Inc. | 2022-01-20 |
| A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors (NCT07554196) | Huahui Health | 2022-01-19 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors (NCT04683939) | BioNTech SE | 2022-01-18 |
| Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors (NCT05228015) | Ikena Oncology | 2022-01-07 |
| Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation (NCT05023655) | Prisma Health-Upstate | 2022-01-06 |
| HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors (NCT04965220) | Shanghai Henlius Biotech | 2022-01-05 |
| Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (NCT05430360) | Grit Biotechnology | 2022-01-04 |
| To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers (NCT05248074) | Abion Inc | 2022-01-04 |
| An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (NCT05166070) | The First Affiliated Hospital with Nanjing Medical University | 2022-01-01 |
| Study of FCN-098 in Patients With Advanced Solid Tumor (NCT05212987) | Fochon Pharmaceuticals, Ltd. | 2021-12-31 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272) | 23andMe, Inc. | 2021-12-29 |
| Study of AK119 in Subjects With Advanced Solid Tumors (NCT05173792) | Akeso | 2021-12-22 |
| Clinical Trial of WBC100 on Advanced Solid Tumor (NCT05100251) | Zhejiang University | 2021-12-17 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (NCT05176483) | Exelixis | 2021-12-14 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (NCT05159245) | Helsinki University Central Hospital | 2021-12-10 |
| Text-based Intervention to Minimize the Time Burden of Routine Cancer Care (NCT05134636) | Abramson Cancer Center at Penn Medicine | 2021-12-06 |
| A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors (NCT05046847) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-11-30 |
| A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors (NCT05093322) | Hutchmed | 2021-11-30 |
| Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (NCT04900519) | Sorrento Therapeutics, Inc. | 2021-11-24 |
| Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers (NCT05205330) | Rottapharm Biotech | 2021-11-23 |
| Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors (NCT05238792) | Children's National Research Institute | 2021-11-17 |
| Exploratory Drug Interaction Study Between SMIs and DOACs (NCT05732350) | Maastricht University Medical Center | 2021-11-11 |
| Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors (NCT05207787) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-11-09 |
| Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors (NCT05547906) | MetaFines | 2021-11-08 |
| A Study of NDI 1150-101 in Patients With Solid Tumors (NCT05128487) | Nimbus Saturn, Inc. | 2021-11-05 |
| A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors (NCT05126927) | SmartNuclide Biopharma | 2021-11-02 |
| A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors (NCT04984668) | Suzhou Kintor Pharmaceutical Inc, | 2021-11-02 |
| A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors (NCT05136937) | Wuxi People's Hospital | 2021-11-01 |
| ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0) (NCT05115500) | Second Affiliated Hospital of Soochow University | 2021-11-01 |
| Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors (NCT05037149) | Sirnaomics | 2021-11-01 |
| A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. (NCT07392736) | Advenchen Laboratories, LLC | 2021-10-26 |
| Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma (NCT05190263) | AIO-Studien-gGmbH | 2021-10-25 |
| Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (NCT04316169) | Medical College of Wisconsin | 2021-10-21 |
| A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors (NCT05150405) | Qilu Pharmaceutical Co., Ltd. | 2021-10-19 |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (NCT04991506) | Elpiscience Biopharma, Ltd. | 2021-10-15 |
| S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (NCT05162755) | Institut de Recherches Internationales Servier | 2021-10-15 |
| Study of Sacituzumab Govitecan in Patients With Solid Tumor (NCT05119907) | Gilead Sciences | 2021-10-12 |
| A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects (NCT05109832) | Impact Therapeutics, Inc. | 2021-10-09 |
| Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (NCT05002868) | Rhizen Pharmaceuticals SA | 2021-10-05 |
| Study of Magrolimab in Patients With Solid Tumors (NCT04827576) | Gilead Sciences | 2021-10-01 |
| Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors (NCT04930432) | Betta Pharmaceuticals Co., Ltd. | 2021-09-24 |
| Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects (NCT05046808) | Jiangsu HengRui Medicine Co., Ltd. | 2021-09-23 |
| A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer (NCT04982926) | Taiho Oncology, Inc. | 2021-09-16 |
| A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05039931) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-09-15 |
| A Study of LP-118 in Patients With Advanced Tumors (NCT05025358) | Guangzhou Lupeng Pharmaceutical Company LTD. | 2021-09-08 |
| A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors (NCT05159388) | Servier Bio-Innovation LLC | 2021-09-08 |